Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetesA scoping review

  1. A. Ruiz-García 1
  2. V. Pallarés-Carratalá 2
  3. A. Serrano-Cumplido 3
  4. C. Escobar-Cervantes 4
  5. A. Barquilla-García 5
  6. J.A. Divisón-Garrote 6
  7. M. Turégano-Yedro 7
  8. M.A. Prieto-Díaz 8
  9. S. Cinza-Sanjurjo 9
  10. F.J. Alonso-Moreno 10
  11. P. Beato-Fernández 11
  12. L. García-Matarín 12
  13. D. Rey-Aldana 13
  14. E. Martín-Rioboó 14
  15. A. Moyá-Amengual 15
  16. R. Crespo-Sabarís 16
  17. A. Piera-Carbonell 17
  18. J.C. Romero-Vigara 18
  19. V. Barrios 19
  20. SEMERGEN Working Group on Hypertension, Cardiovascular Disease
  1. 1 European University of Madrid, Villaviciosa de Odón, Madrid, Spain
  2. 2 Medicine Department, Jaume I University, Castellón, Spain
  3. 3 Family Medicine, Getxo, Bizkaia, Spain
  4. 4 Cardiology Service, La Paz University Hospital, Madrid, Spain
  5. 5 Trujillo Primary Care Team, Clinics of Herguijuela and Conquista de la Sierra), Cáceres, Spain
  6. 6 Casas Ibáñez Health Center, Fuentealbilla Clinic, Albacete, Spain
  7. 7 Aldea Moret Health Center, Cáceres, Spain
  8. 8 Vallobín – La Florida Health Center, Oviedo, Spain
  9. 9 Porto do Son Health Center, Santiago de Compostela Health Area, Santiago de Compostela, Spain
  10. 10 Sillería Health Center, Toledo, Spain
  11. 11 Premia de Mar Primary Care Center, Catalan Institute of Health, Barcelona, Spain
  12. 12 Aguadulce Sur Health Center, Roquetas de Mar, Almería, Spain
  13. 13 Estrada Health Center, Pontevedra, Spain
  14. 14 Maimónides Institute for Biomedical Research of Córdoba (IMIBIC), Reina Sofía Hospital, Poniente clinical management unit, Córdoba, Spain
  15. 15 Occupational Medicine, Santa Catalina Health Center, Palma de Mallorca, Islas Baleares, Spain
  16. 16 Primary Care Management of La Rioja Health Service, Logroño, La Rioja, Spain
  17. 17 Luanco Health Center, Gozón, Asturias, Spain
  18. 18 Corella Health Center, Corella, Navarra, Spain
  19. 19 Cardiology Service, Ramón y Cajal University Hospital, Madrid, Spain
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2022

Número: 4

Páxinas: 275-292

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2021.12.002 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Obxectivos de Desenvolvemento Sustentable

Resumo

Antecedentes La eficacia y la seguridad de la profilaxis con ácido acetilsalicílico (AAS) para la prevención primaria de la enfermedad cardiovascular arteriosclerótica (ECVA) siguen siendo controvertidas en personas con diabetes (DM) sin ECVA, ya que el posible aumento del riesgo de hemorragias graves podría superar la posible disminución del riesgo de mortalidad y de los principales episodios adversos cardiovasculares (MACE) considerados individualmente o en conjunto. Objetivo Evaluar el riesgo-beneficio de la profilaxis con AAS en prevención primaria en personas con DM y comparar las recomendaciones de las guías de práctica clínica con los resultados de los metaanálisis (MA) y revisiones sistemáticas (RS). Material y métodos Se realizaron búsquedas en Medline, Google Scholar, Embase y Biblioteca Cochrane de RS y MA publicados desde 2009 hasta 2020 que compararan los efectos de AAS versus placebo o control en seguimiento durante al menos un año en personas con DM sin ECVA. Se valoraron la heterogeneidad entre los ensayos clínicos aleatorizados (ECA) incluidos en las RS y MA. Se mostraron los resultados cardiovasculares de eficacia (muerte por cualquier causa [MCC], muerte cardiovascular [MCV], infarto de miocardio [IM], ictus y MACE) y de seguridad (episodios hemorrágicos importantes [EHI], episodios hemorrágicos gastrointestinales importantes [EHGI], hemorragias intracraneales y extracraneales). Resultados Se valoraron las recomendaciones de 12 guías de práctica clínica. Se evaluaron los resultados de 25 RS y MA que incluyeron un total de 20 ECA. Ningún MA ni RS mostró que la profilaxis con AAS disminuyera el riesgo de MCC, MCV o IM. Solo dos de los 19 SR y MA que evaluaron el ictus isquémico mostraron una disminución en el riesgo de ictus (media 20,0% [DE ± 5,7]), rozando la significación estadística. Casi la mitad de los MA y SR mostraron una reducción del riesgo del criterio de valoración compuesto MACE (media 10,5% [DE ± 3,3]) al borde de la significación estadística. Los aumentos significativos en el riesgo de EHGI oscilaron entre el 35 y el 55%. Los aumentos significativos en el riesgo de EHI y hemorragia extracraneal fueron del 33,4% (DE ± 14,9) y del 54,5% (DE ± 0,7), respectivamente. Conclusión La valoración global de riesgo-beneficio de la profilaxis con AAS en prevención primaria sugiere que esta no se debería aplicar en personas con DM.

Referencias bibliográficas

  • C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, R. Peto, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet, 373 (2009), pp. 1849-1860, 10.1016/S0140-6736(09)60503-1 View PDFView Record in ScopusGoogle Scholar
  • D.K. Arnett, R.S. Blumenthal, M.A. Albert, A.B. Buroker, Z.D. Goldberger, E.J. Hahn, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll Cardiol, 74 (2019), pp. e177-e232, 10.1016/j.jacc.2019.03.010 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F. Mach, C. Baigent, A.L. Catapano, K.C. Koskinas, M. Casula, L. Badimon, et al. ESC Scientific Document Group 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J, 41 (2020), pp. 111-188, 10.1093/eurheartj/ehz455 View PDFView Record in ScopusGoogle Scholar
  • F.L.J. Visseren, F. Mach, Y.M. Smulders, D. Carballo, K.C. Koskinas, M. Bäck, et al. ESC Scientific Document Group 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Eur Heart J, 42 (2021), pp. 3227-3337, 10.1093/eurheartj/ehab484 View PDFGoogle Scholar
  • M.F. Piepoli, A. Abreu, C. Albus, M. Ambrosetti, C. Brotons, A.L. Catapano, et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology Eur J Prev Cardiol, 27 (2020), pp. 181-205, 10.1177/2047487319893035 View PDFView Record in ScopusGoogle Scholar
  • H. McGuire, D. Longson, A. Adler, A. Farmer, I. Lewin Guideline Development Group Management of type 2 diabetes in adults: summary of updated NICE guidance BMJ, 353 (2016), p. i1575, 10.1136/bmj.i1575 View PDFGoogle Scholar
  • A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blonde, Z.T. Bloomgarden, M.A. Bush, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary Endocr Pract, 25 (2019), pp. 69-100, 10.4158/CS-2018-0535 View PDFView Record in ScopusGoogle Scholar
  • J.A. Stone, R.L. Houlden, P. Lin, J.A. Udell, S. Verma Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: cardiovascular protection in people with diabetes Can J Diabetes, 42 (2018), pp. S162-S169, 10.1016/j.jcjd.2017.10.024 View PDFView Record in ScopusGoogle Scholar
  • F. Cosentino, P.J. Grant, V. Aboyans, C.J. Bailey, A. Ceriello, V. Delgado, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Eur Heart J, 41 (2020), pp. 255-323, 10.1093/eurheartj/ehz486 View PDFView Record in ScopusGoogle Scholar
  • A. Nicolucci, G. De Berardis, M. Sacco, G. Tognoni AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions Eur Heart J, 28 (2007), pp. 1925-1927, 10.1093/eurheartj/ehm248 View PDFView Record in ScopusGoogle Scholar
  • C. Sirois, P. Poirier, J. Moisan, J.P. Grégoire The benefit of aspirin therapy in type 2 diabetes: what is the evidence? Int J Cardiol, 129 (2008), pp. 172-179, 10.1016/j.ijcard.2008.01.030 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.O. Vandvik, A.M. Lincoff, J.M. Gore, D.D. Gutterman, F.A. Sonnenberg, P. Alonso-Coello, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines Chest, 141 (2012), pp. e637S-e638S, 10.1378/chest.11-2306 View PDFGoogle Scholar
  • J.M. Gaziano, C. Brotons, R. Coppolecchia, C. Cricelli, H. Darius, P.B. Gorelick, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial Lancet, 392 (2018), pp. 1036-1046, 10.1016/S0140-6736(18)31924-X ArticleDownload PDFView Record in ScopusGoogle Scholar
  • L. Bowman, M. Mafham, K. Wallendszus, W. Stevens, G. Buck, J. Barton, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus N Engl J Med, 379 (2018), pp. 1529-1539, 10.1056/NEJMoa1804988 View PDFView Record in ScopusGoogle Scholar
  • J.J. McNeil, R. Wolfe, R.L. Woods, A.M. Tonkin, G.A. Donnan, M.R. Nelson, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly N Engl J Med, 379 (2018), pp. 1509-1518, 10.1056/NEJMoa1805819 View PDFView Record in ScopusGoogle Scholar
  • A.C. Tricco, E. Lillie, W. Zarin, K.K. O’Brien, H. Colquhoun, D. Levac, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation Ann Intern Med, 169 (2018), pp. 467-473, 10.7326/M18-0850 View PDFGoogle Scholar
  • J.P.T. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman Measuring inconsistency in meta-analyses BMJ, 327 (2003), pp. 557-560, 10.1136/bmj.327.7414.557 View PDFGoogle Scholar
  • G.L. Booth, M.K. Kapral, K. Fung, J.V. Tu Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study Lancet, 368 (2006), pp. 29-36, 10.1016/S0140-6736(06)68967-8 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Haffner, S. Lehto, T. Ronnemaa, K. Pyörälä, M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med, 339 (1998), pp. 229-234, 10.1056/NEJM199807233390404 View PDFView Record in ScopusGoogle Scholar
  • Emerging Risk Factors Collaboration, N. Sarwar, P. Gao, S.R. Seshasai, R. Gobin, S. Kaptoge, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet, 375 (2010), pp. 2215-2222, 10.1016/S0140-6736(10)60484-9 View PDFView Record in ScopusGoogle Scholar
  • S. Seidu, X. Cos, S. Brunton, S.B. Harris, S.P.O. Jansson, M. Mata-Cases, et al. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: a position statement by Primary Care Diabetes Europe Primary Care Diabetes, 15 (2021), pp. 31-51, 10.1016/j.pcd.2020.05.004 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • G. De Berardis, M. Sacco, G.F.M. Strippoli, F. Pellegrini, G. Graziano, G. Gianni Tognoni, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ, 339 (2009), p. b4531, 10.1136/bmj.b4531 View PDFView Record in ScopusGoogle Scholar
  • A.D. Calvin, N.R. Aggarwal, M.H. Murad, Q. Shi, M.B. Elamin, J.B. Geske, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes Diabetes Care, 32 (2009), pp. 2300-2306, 10.2337/dc09-1297 View PDFView Record in ScopusGoogle Scholar
  • N. Younis, S. Williams, B. Ammori, H. Soran Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Expert Opin Pharmacother, 11 (2010), pp. 1459-1466, 10.1517/14656561003792538 View PDFView Record in ScopusGoogle Scholar
  • C. Zhang, A. Sun, P. Zhang, C. Wu, S. Zhang, M. Fu, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Diabetes Res Clin Pract, 87 (2010), pp. 211-218, 10.1016/j.diabres.2009.09.029 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S. Butalia, A.A. Leung, W.A. Ghali, D.M. Rabi Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis Cardiovasc Diabetol, 10 (2011), p. 25, 10.1186/1475-2840-10-25 View PDFView Record in ScopusGoogle Scholar
  • S. Stavrakis, J.A. Stoner, M. Azar, S. Wayangankar, U. Thadani Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Am J Med Sci, 341 (2011), pp. 1-9, 10.1097/MAJ.0b013e3181f1fba8 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • S.H. Simpson, J.M. Gamble, L. Mereu, T. Chambers Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis J Gen Intern Med, 26 (2011), pp. 1336-1344, 10.1007/s11606-011-1757-y View PDFView Record in ScopusGoogle Scholar
  • M. Pignone, M.J. Alberts, J.A. Colwell, M. Cushman, S.E. Inzucchi, D. Mukherjee, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes J Am Coll Cardiol, 55 (2010), pp. 2878-2886, 10.1161/CIR.0b013e3181e3b133 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P. Sutcliffe, M. Connock, T. Gurung, K. Freeman, S. Johnson, N.B. Kandala, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews Health Technol Assess, 17 (2013), pp. 1-253, 10.3310/hta17430 View PDFGoogle Scholar
  • M. Xie, Z. Shan, Y. Zhang, S. Chen, W. Yang, W. Bao, et al. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status PLoS ONE, 9 (2014), p. e90286, 10.1371/journal.pone.0090286 View PDFView Record in ScopusGoogle Scholar
  • E.P. Whitlock, B.U. Burda, S.B. Williams, J.M. Guirguis-Blake, C.V. Evans Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med, 164 (2016), pp. 826-835, 10.7326/M15-2112 View PDFView Record in ScopusGoogle Scholar
  • S.K. Kunutsor, S. Seidu, K. Khunti Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials Diabet Med, 34 (2017), pp. 316-327, 10.1111/dme.13133 View PDFView Record in ScopusGoogle Scholar
  • H.K. Abdelaziz, M. Saad, N.V.K. Pothineni, M. Megaly, R. Potluri, M. Saleh, et al. Aspirin for primary prevention of cardiovascular events J Am Coll Cardiol, 73 (2019), pp. 2915-2929, 10.1016/j.jacc.2019.03.501 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A.N. Mahmoud, M.M. Gad, A.Y. Elgendy, I.Y. Elgendy, A.A. Bavry Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials Eur Heart J, 40 (2019), pp. 607-617, 10.1093/eurheartj/ehy813 View PDFView Record in ScopusGoogle Scholar
  • M. Barbarawi, B. Kheiri, Y. Zayed, I. Gakhal, A. Al-Abdouh, O. Barbarawi, et al. Aspirin efficacy in primary prevention: a metaanalysis of randomized controlled trials High Blood Press Cardiovasc Prev, 26 (2019), pp. 283-291, 10.1007/s40292-019-00325-5 View PDFView Record in ScopusGoogle Scholar
  • M. Christiansen, E.L. Grove, A.M. Hvas Primary Prevention of cardiovascular events with aspirin: toward more harm than benefit – a systematic review and meta-analysis Semin Thromb Hemost, 45 (2019), pp. 478-489, 10.1055/s-0039-1687905 View PDFView Record in ScopusGoogle Scholar
  • W.Y. Huang, J.L. Saver, Y.L. Wu, C.J. Lin, M. Lee, B. Ovbiagele Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis JAMA Neurol, 76 (2019), pp. 906-914, 10.1001/jamaneurol.2019.1120 View PDFView Record in ScopusGoogle Scholar
  • S.L. Zheng, A.J. Roddick Association of aspirin use for primary prevention with cardiovascular events and bleeding events. A systematic review and meta-analysis JAMA, 321 (2019), pp. 277-287, 10.1001/jama.2018.20578 View PDFView Record in ScopusGoogle Scholar
  • G. Gelbenegger, M. Postula, L. Pecen, S. Halvorse, M. Lesiak, C. Schoergenhofer, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups BMC Med, 17 (2019), p. 198, 10.1186/s12916-019-1428-0 View PDFView Record in ScopusGoogle Scholar
  • M.H. Lin, C.H. Lee, C. Lin, Y.F. Zou, C.H. Lu, C.H. Hsieh, et al. Low-dose aspirin for the primary prevention of cardiovascular disease in diabetic individuals: a meta-analysis of randomized control trials and trial sequential analysis J Clin Med, 8 (2019), p. 609, 10.3390/jcm8050609 View PDFGoogle Scholar
  • S. Seidu, S.K. Kunutsor, H.D. Sesso, J.M. Gaziano, J.E. Buring, M.C. Roncaglioni, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials Cardiovasc Diabetol, 18 (2019), p. 70, 10.1186/s12933-019-0875-4 View PDFView Record in ScopusGoogle Scholar
  • S.U. Khan, Z.U.A. Asad, M.U. Khan, S. Talluri, F. Ali, M.S. Khan, et al. Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: an updated systematic review and meta-analysis Eur J Prev Cardiol, 27 (2020), pp. 2034-2041, 10.1177/2047487319825510 View PDFView Record in ScopusGoogle Scholar
  • D. Caldeira, M. Alves, C. David, J. Costa, J.J. Ferreira, F.J. Pinto Aspirin in the primary prevention of cardiovascular disease on diabetic patients: systematic review and meta-analysis Prim Care Diab, 14 (2020), pp. 213-221, 10.1016/j.pcd.2019.11.004 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R. Peto, R. Gray, R. Collins, K. Wheatley, C. Hennekens, K. Jamrozik, et al. Randomised trial of prophylactic daily aspirin in British male doctors Br Med J (Clin Res Ed), 296 (1988), pp. 313-316, 10.1136/bmj.296.6618.313 View PDFGoogle Scholar
  • C.H. Hennekens, Steering Committee of the Physicians’ Health Study Research Group Final report on the aspirin component of the ongoing Physicians’ Health Study N Engl J Med, 321 (1989), pp. 129-135, 10.1056/NEJM198907203210301 View PDFGoogle Scholar
  • A. Kassoff, S.M. Buzney, J.W. McMeel, WeiterJJ, G.J. Doyle, R.L. Immerman, et al., ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus – early treatment diabetic-retinopathy study report-14 JAMA, 268 (1992), pp. 1292-1300, 10.1001/jama.1992.03490100090033 View PDFGoogle Scholar
  • R. Cote, R.N. Battista, M. Abrahamowicz, Y. Langlois, F. Bourque, A. Mackey, et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing Ann Intern Med, 123 (1995), pp. 649-655, 10.7326/0003-4819-123-9-199511010-00002 View PDFView Record in ScopusGoogle Scholar
  • L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet, 351 (1998), pp. 1755-1762, 10.1016/s0140-6736(98)04311-6 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.M. Ridker, N.R. Cook, I.M. Lee, D. Gordon, J.M. Gaziano, J.E. Manson, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med, 352 (2005), pp. 1293-1304, 10.1056/NEJMoa050613 View PDFGoogle Scholar
  • M. Sacco, F. Pellegrini, M.C. Roncaglioni, F. Avanzini, G. Tognoni, A. Nicolucci, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial Diabetes Care, 26 (2003), pp. 3264-3272, 10.2337/diacare.26.12.3264 View PDFView Record in ScopusGoogle Scholar
  • R. Landolfi, R. Marchioli, J. Kutti, H. Gisslinger, G. Tognoni, C. Patrono, et al. Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med, 350 (2004), pp. 114-124, 10.1056/NEJMoa035572 View PDFView Record in ScopusGoogle Scholar
  • M. Catalano, G. Born, R. Peto, Critical Leg Ischaemia Prevention Study (CLIPS) Group Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial J Intern Med, 261 (2007), pp. 276-284, 10.1111/j.1365-2796.2006.01763.x View PDFView Record in ScopusGoogle Scholar
  • D. Erkan, M.J. Harrison, R. Levy, M. Peterson, M. Petri, L. Sammaritano, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals Arthritis Rheum, 56 (2007), pp. 2382-2391, 10.1002/art.22663 View PDFView Record in ScopusGoogle Scholar
  • H. Ogawa, M. Nakayama, T. Morimoto, S. Uemura, M. Kanauchi, N. Doi, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA, 300 (2008), pp. 2134-2141, 10.1001/jama.2008.623 View PDFView Record in ScopusGoogle Scholar
  • J. Belch, A. MacCuish, I. Campbell, S. Cobbe, R. Taylor, R. Prescott, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ, 337 (2008), p. a1840, 10.1136/bmj.a1840 View PDFView Record in ScopusGoogle Scholar
  • F.G. Fowkes, J.F. Price, M.C. Stewart, I. Butcher, G.C. Leng, A.C. Pell, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA, 303 (2010), pp. 841-848, 10.1001/jama.2010.221 View PDFView Record in ScopusGoogle Scholar
  • Y. Ikeda, K. Shimada, T. Teramoto, S. Uchiyama, T. Yamazaki, S. Oikawa, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors. A randomized clinical trial JAMA, 312 (2014), pp. 2510-2520, 10.1001/jama.2014.15690 View PDFView Record in ScopusGoogle Scholar
  • Y. Saito, S. Okada, H. Ogawa, H. Soejima, M. Sakuma, M. Nakayama, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial Circulation, 135 (2017), pp. 659-670, 10.1161/CIRCULATIONAHA.116.025760 View PDFView Record in ScopusGoogle Scholar
  • M. Goicoechea, S.G. de Vinuesa, B. Quiroga, E. Verde, C. Bernis, E. Morales, et al. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study) Cardiovasc Drugs Ther, 32 (2018), pp. 255-263, 10.1007/s10557-018-6802-1 View PDFView Record in ScopusGoogle Scholar
  • A. Ruiz-García, E. Arranz-Martínez, J.C. García-Álvarez, M.E. García-Fernández, D. Palacios-Martínez, A. Montero-Costa, et al. Prevalence of diabetes mellitus in Spanish primary care setting and its association with cardiovascular risk factors and cardiovascular diseases. SIMETAP-DM study Clin Investig Arterioscler, 32 (2020), pp. 15-26, 10.1016/j.arteri.2019.03.006 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.M. Guirguis-Blake, C.V. Evans, C.A. Senger, E.A. O’Connor, E.P. Whitlock Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force Ann Intern Med, 164 (2016), pp. 804-813, 10.7326/M15-2113 View PDFView Record in ScopusGoogle Scholar
  • L.A. García Rodríguez, M. Martín-Pérez, C.H. Hennekens, P.M. Rothwell, A. Lanas Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies PLoS ONE, 11 (2016), p. e0160046, 10.1371/journal.pone.0160046 View PDFGoogle Scholar
  • W.S. Jones, H. Mulder, L.M. Wruck, M.J. Pencina, S. Kripalani, D. Muñoz, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease N Engl J Med, 384 (2021), pp. 1981-1990, 10.1056/NEJMoa2102137 View PDFView Record in ScopusGoogle Scholar
Fonte de datos: Dialnet